Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.


PPD names Pfizer executive David Simmons its new CEO

Clinical research organization PPD has hired a Pfizer (NYSE:PFE) veteran to become its new CEO. David Simmons brings 15 years experience at the world’s largest pharmaceutical company to PPD, which is one of the largest CROs in the pharmaceutical services industry. The CEO post became vacant after PPD was taken private in a $3.9 billion […]

Devices & Diagnostics

Antares inks licensing agreement with Pfizer

Antares Pharma (AMEX:AIS) has inked a licensing  agreement with Pfizer (NYSE:PFE) to provide one of its drug-delivery technologies to Pfizer’s consumer healthcare business arm for an unnamed product for North America. Pfizer, in New York, will be responsible for clinical development, manufacturing and commercialization of the product. Ewing, New Jersey-based Antares will receive up-front payments, […]


PFE gives ICGN shareholders last chance to accept $56M deal

Nearly one-third of Icagen (NASDAQ:ICGN) shareholders have yet to accept Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company and the pharmaceutical giant is giving them one last chance. The expiration date for the offer at $6 per share in cash has been extended one week. But Pfizer, which extended its tender offer […]


Pfizer secures enough shares for Icagen acquisition

Pfizer‘s (NYSE:PFE) Icagen (NASDAQ:ICGN) acquisition is a go. After two extensions last week, Pfizer announced today that it has enough shares tendered for sale  for the $56 million cash deal to proceed at the price of $6 per share. As of the 6 p.m. deadline on Sept. 2, 64 percent of outstanding shares of Icagen, […]


GSK, PFE joint venture sues to block HIV generic from Teva

GlaxoSmithKline (NYSE:GSK) is moving to protect its top-selling HIV drug Epzicom from generic drug competition. ViiV Healthcare, the HIV joint venture of GSK and Pfizer (NYSE:PFE), is suing Teva Pharmaceutical (NASDAQ:TEVA) for infringing on HIV drug Epzicom in violation of the drug’s patent, Bloomberg News reports. The Aug. 5 complaint was filed in federal court […]


Pfizer-Icagen deal faces problem: Merlin Nexus opposes price

Pfizer’s (NYSE:PFE) $56 million bid to acquire Icagen (NASDAQ:ICGN) faces a big hurdle —  two of Icagen’s largest shareholders. Merlin Nexus and New Leaf Venture Partners, two firms holding Icagen stock, submitted a July 28 letter to the Icagen board contesting the deal, saying they “believe the purchase price dramatically undervalues Icagen’s assets and is […]


Pfizer-Icagen merger: What ICGN could bring to PFE’s portfolio

Pfizer (NYSE:PFE) is now talking about a possible acquisition of Icagen (NASDAQ:ICGN). But, already, Pfizer is Icagen’s primary supporter. Icagen, which is based in Durham, North Carolina, has relied on a 2007 partnership with Pfizer to develop drug candidates to treat pain. Icagen’s compounds modulate ion channels, which are protein structures found in the cells […]